JPH0326175B2 - - Google Patents
Info
- Publication number
- JPH0326175B2 JPH0326175B2 JP58147231A JP14723183A JPH0326175B2 JP H0326175 B2 JPH0326175 B2 JP H0326175B2 JP 58147231 A JP58147231 A JP 58147231A JP 14723183 A JP14723183 A JP 14723183A JP H0326175 B2 JPH0326175 B2 JP H0326175B2
- Authority
- JP
- Japan
- Prior art keywords
- present
- protein
- hypoglycemic agent
- protein polysaccharide
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 150000004676 glycans Chemical class 0.000 claims description 15
- 229920001282 polysaccharide Polymers 0.000 claims description 15
- 239000005017 polysaccharide Substances 0.000 claims description 15
- 239000003472 antidiabetic agent Substances 0.000 claims description 12
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000221198 Basidiomycota Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000005199 ultracentrifugation Methods 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims 1
- 238000000691 measurement method Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 15
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 108010001062 polysaccharide-K Proteins 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000222356 Coriolus Species 0.000 description 1
- 241000116710 Ferula foetidissima Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- -1 valine and leucine Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58147231A JPS6045532A (ja) | 1983-08-11 | 1983-08-11 | 血糖降下剤 |
| DE3448152A DE3448152C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448153A DE3448153C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448154A DE3448154C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448150A DE3448150C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448145A DE3448145C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE19843429551 DE3429551A1 (de) | 1983-08-11 | 1984-08-10 | Pharmazeutische zubereitung, die ein glycoprotein enthaelt |
| DE3448148A DE3448148C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448155A DE3448155C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448151A DE3448151C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448144A DE3448144C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448149A DE3448149C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| US06/898,900 US4820689A (en) | 1983-08-11 | 1986-08-22 | Pharmaceutical composition containing a glycoprotein |
| US07/285,664 US5008243A (en) | 1983-08-11 | 1988-12-16 | Pharmaceutical composition containing a glycoprotein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58147231A JPS6045532A (ja) | 1983-08-11 | 1983-08-11 | 血糖降下剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6045532A JPS6045532A (ja) | 1985-03-12 |
| JPH0326175B2 true JPH0326175B2 (enrdf_load_stackoverflow) | 1991-04-10 |
Family
ID=15425532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58147231A Granted JPS6045532A (ja) | 1983-08-11 | 1983-08-11 | 血糖降下剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6045532A (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63161929A (ja) * | 1986-12-25 | 1988-07-05 | 旭光学工業株式会社 | 内視鏡の体腔内圧調整装置 |
| CA2156767A1 (en) * | 1994-08-25 | 1996-02-26 | Kenichi Matsunaga | Binding agent for growth factor |
| WO2002098440A1 (fr) * | 2001-06-01 | 2002-12-12 | Ajinomoto Co., Inc. | Traitement antidiabetique |
-
1983
- 1983-08-11 JP JP58147231A patent/JPS6045532A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6045532A (ja) | 1985-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Conti et al. | Protective activity of silipide on liver damage in rodents | |
| WO1999025357A1 (en) | USE OF 9-DEOXY-2', 9-α-METHANO-3- OXA-4,5,6- TRINOR-3, 7-(1',3'-INTERPHENYLENE) -13,14-DIHYDRO- PROSTAGLANDIN F1 TO TREAT PERIPHERAL VASCULAR DISEASE | |
| IL134163A (en) | Combined use of chromium and biotin for the preparation of pharmaceuticals and such devices | |
| USRE39480E1 (en) | Chromium/biotin treatment of type II diabetes | |
| US3895107A (en) | CSA and CSC in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals | |
| JP2526059B2 (ja) | 抗潰瘍剤 | |
| KR101701943B1 (ko) | 당뇨병의 치료 또는 예방약 | |
| JPH0326175B2 (enrdf_load_stackoverflow) | ||
| REHFELD et al. | The effect of gastrin on basal and aminoacid‐stimulated insulin and glucagon secretion in man | |
| SE457958B (sv) | Vattenloeslig hemin-arginat eller hemin-lysinat-foerening, foerfarande foer framstaellning daerav samt anvaendning daerav foer tillverkning av medicinska kompositioner | |
| JPH04235918A (ja) | 脂肪肝治療剤 | |
| JPH0331177B2 (enrdf_load_stackoverflow) | ||
| JPH0326172B2 (enrdf_load_stackoverflow) | ||
| JPH0331178B2 (enrdf_load_stackoverflow) | ||
| JPH0326174B2 (enrdf_load_stackoverflow) | ||
| KR0171188B1 (ko) | 당뇨병 치료용 제약 조성물 | |
| JPH0326171B2 (enrdf_load_stackoverflow) | ||
| JPH0361651B2 (enrdf_load_stackoverflow) | ||
| JPH05170659A (ja) | 血中アルコール濃度低下用組成物 | |
| JP4178584B2 (ja) | 抗アレルギー剤 | |
| EP0295962A2 (en) | Protein-polysaccharide for treating retroviral infections | |
| EP3402505A1 (en) | Pharmaceutical formulations for the treatment of diabetes | |
| JPH0331176B2 (enrdf_load_stackoverflow) | ||
| JPH0326173B2 (enrdf_load_stackoverflow) | ||
| JPS5834446B2 (ja) | 消炎剤 |